絞り込み

16644

広告

いくらあれば革命起こせる ネット資金調達先駆者の本気 (朝日新聞)

拡大する移転した新しいオフィスはガラス張り。「光が入る空間が良かった。気持ちまで明るくなる。今日も会社に来てがんばろうって思える、会社に行きたくなるオフィス」=...

  1. 時代の変化を映した改正薬機法、薬局・薬剤...
  2. 専門家なら怒鳴られても薬を早く出すな (...
  3. これからの時代の薬剤師はDon’t wa...
  4. 竹のストロー、インドの山村に根差す持続可...

ニュース一覧

スターを付ける スターを付ける     (21view , 0users)

Full Text Sources

Miscellaneous

Dipeptidyl peptidases (DPPs) are proteolytic enzymes that are ideal therapeutic targets in human diseases. Indeed, DPP4 inhibitors are widely used in clinical practice as anti-diabetic agents. In this paper, we show that DPP4 inhibitors also induced cell death in multiple human myeloma cells. Among five DPP4 inhibitors, only two of them, vildagliptin and saxagliptin, exhibited apparent cytotoxic effects on myeloma cell lines, without any difference in suppression of DPP4 activity. As these two DPP4 inhibitors are known to have off-target effects against DPP8/9, we employed the specific DPP8/9 inhibitor 1G244. 1G244 demonstrated anti-myeloma effects on several cell lines and CD138+ cells from patients as well as in murine xenograft model. Through siRNA silencing approach, we further confirmed that DPP8 but not DPP9 is a key molecule in inducing cell death induced by DPP8/9 inhibition. In fact, the expression of DPP8 in CD38+ cells from myeloma patients was higher than that of healthy volunteers. DPP8/9 inhibition induced apoptosis, as evidenced by activated form of PARP, caspases-3 and was suppressed by the pan-caspase inhibitor Z-VAD-FMK. Taken together, these results indicate that DPP8 is a novel therapeutic target for myeloma treatment.
PMID: 31792328 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード